<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02270255</url>
  </required_header>
  <id_info>
    <org_study_id>4242</org_study_id>
    <nct_id>NCT02270255</nct_id>
  </id_info>
  <brief_title>Superior Hypogastric Nerve Block for Pain Control Post-uterine Fibroid Embolization</brief_title>
  <official_title>Prospective Blinded Study Looking at PO/IV Analgesia Alone Versus PO/IV Analgesia With Superior Hypogastric Nerve Block for Uterine Artery Embolization Pain Management</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>McGill University Health Centre/Research Institute of the McGill University Health Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>McGill University Health Centre/Research Institute of the McGill University Health Centre</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Uterine fibroid embolization (UFE) is now an accepted treatment of uterine fibroids. However
      the procedure is often very painful and, in many centres, patients are admitted overnight
      with patient controlled analgesic (PCA) pumps for pain control and discharged the next day
      with heavy pain medications. The goal of this study is to evaluate the effectiveness of a
      superior hypogastric nerve block (SHGNB) in controlling the pain post-UFE.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a double blinded study in which the patients and the primary operators of the UFE as
      well as the post-procedural caregivers are blinded to whether the patients have received a
      sham procedure (injection of xylocaine in the skin in the peri-umbilical region) or the
      superior hypogastric nerve block.

      The superior hypogastric nerve block (SHGNB) consists of advancing a 21g Chiba needle via an
      anterior approach up to the superior hypogastric nerve plexus and injecting 20cc of 0.75%
      Ropivacaine which is a long lasting local anesthetic agent. The nerve plexus is positioned
      below the aortic bifurcation along the anterior surface of the vertebral body. By
      fluoroscopy, the location can be identified by having a catheter crossing the aortic
      bifurcation. That way, we are able to target, under fluoroscopy, the anterior surface of the
      vertebral body just below the catheter.

      Our UFE starts with a right common femoral artery (CFA) access. The catheter is crossed to
      the left side and the left uterine artery embolized with polyvinyl alcohol (PVA) 500-700
      particles. The operator will then leave the room. Another operator will come and perform
      either the hypogastric nerve block or the sham procedure (injection of xylocaine in the
      periumbilical subcutaneous tissues). If the hypogastric nerve block is done, the needle is
      advanced into position via an anterior periumbilical approach under fluoroscopic guidance.
      Once the bony surface is contacted, 3 cc of xylocaine is injected to numb the area and then
      3-6 cc of contrast is injected to ensure that it drapes the anterior vertebral body surface.
      If it spreads along both sides of the vertebral body and there is no vascular intravasation
      of contrast, the 20 cc of Ropivacaine is injected. If it only drapes one side, 10 cc is
      injected and the needle repositioned to the other side, the position verified with contrast,
      and the left over 10 cc of Ropivacaine injected.

      After the block or sham procedure is done, the primary operator enters the room again and the
      UFE completed with embolization of the right uterine artery.

      The patient is transferred to the recovery room and monitored. Pain medication including
      fentanyl and midazolam are offered at routine interval or on patient request. Pain scales are
      measured routinely and the patient is discharge home with a pain survey with visual analog
      pain scales to be performed routinely for 10 days.

      The patient is followed up in 4-6 months with a follow-up magnetic resonance imaging (MRI)
      and consultation to look at the results of the procedure.

      Comparison of the pain scale reports and use of pain medication will be evaluated between
      both groups to determine if there is a statistically significant difference.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Actual">November 1, 2017</completion_date>
  <primary_completion_date type="Actual">November 1, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>mg Equivalent Morphine Used Until Discharge From Recovery Room to Control Pain Level Below 4/10 (VAS)</measure>
    <time_frame>6 hrs (from time of end of UFE to time of discharge from recovery room)</time_frame>
    <description>mg equivalent morphine used until discharge from recovery room to maintain pain level below 4/10 (visual analog scale 0/10=no pain to 10/10=worse pain the patient could imagine)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Serious Adverse Reactions From Superior Hypogastric Nerve Block</measure>
    <time_frame>10 days</time_frame>
    <description>Number of patients with Grade C/D/E/F adverse events (Society of Interventional Radiology (SIR) Classification). Per Society of Interventional Radiology (SIR) Classification: Grade C, require therapy, brief hospitalization (&lt;48 hours); Grade D, require major therapy, unplanned increased level of care, prolonged hospitalization (&gt;48 hours); Grade E, permanent adverse sequelae; Grade F, death.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Leiomyoma</condition>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Sham procedure. Subcutaneous injection of 5cc of 1% Xylocaine in the periumbilical region.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sup Hypogastric Nerve block group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Superior hypogastric nerve block performed during UFE. 20cc of 0.75% Ropivacaine injected at the superior hypogastric nerve plexus.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Superior hypogastric nerve block</intervention_name>
    <description>21g Chiba needle advanced into the superior hypogastric plexus via an anterior infraumbilical approach using the arterial catheter as a fluoroscopic landmark to target the vertebral body below.</description>
    <arm_group_label>Sup Hypogastric Nerve block group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.75% Ropivacaine</intervention_name>
    <description>20 ml of 0.75% Ropivacaine</description>
    <arm_group_label>Sup Hypogastric Nerve block group</arm_group_label>
    <other_name>Naropin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Subcutaneous injection</intervention_name>
    <description>Injection into subcutaneous tissues in periumbilical region</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1% Xylocaine</intervention_name>
    <description>5ml of 1% Xylocaine</description>
    <arm_group_label>Control group</arm_group_label>
    <other_name>Lidocaine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. All women with symptomatic fibroids or adenomyosis that have requested and been
             approved for uterine artery embolization

          2. Ability to comply with the requirements of the study procedures

        Exclusion Criteria:

          1. Patients in whom the vascular anatomy prevents access to the superior hypogastric
             nerve plexus safely

          2. Patients who have known allergy to the anesthetic agent

          3. Patients with signs of skin infection at the entry site of the needle used to place
             the nerve block

          4. Patients with signs of infection such as fever

          5. Patients with history of inflammatory bowel disease of with signs of colitis

          6. Patients with uncorrectable abnormal coagulation status (INR &gt;1.5 and plt &lt; 50000
             without use of anticoagulation agents)

          7. Patients with preexisting conditions, which, in the opinion of the investigator,
             interfere with the conduct of the study.

          8. Patients who are uncooperative, cannot follow instructions, or who are unlikely to
             comply with follow-up appointments or fill-out the post-procedural pain
             questionnaires.

          9. Patients with a mental state that may preclude completion of the study procedure or is
             unable to provide informed consent
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Louis-Martin NJ Boucher, MD/PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>McGill University Health Centre/Research Institute of the McGill University Health Centre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>McGill University Health Centre - Royal Victoria Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3A 1A1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Rasuli P, Jolly EE, Hammond I, French GJ, Preston R, Goulet S, Hamilton L, Tabib M. Superior hypogastric nerve block for pain control in outpatient uterine artery embolization. J Vasc Interv Radiol. 2004 Dec;15(12):1423-9.</citation>
    <PMID>15590800</PMID>
  </reference>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>October 16, 2014</study_first_submitted>
  <study_first_submitted_qc>October 17, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 21, 2014</study_first_posted>
  <results_first_submitted>March 12, 2019</results_first_submitted>
  <results_first_submitted_qc>June 17, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">August 5, 2019</results_first_posted>
  <last_update_submitted>August 2, 2019</last_update_submitted>
  <last_update_submitted_qc>August 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>McGill University Health Centre/Research Institute of the McGill University Health Centre</investigator_affiliation>
    <investigator_full_name>Louis-martin Boucher</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>embolization</keyword>
  <keyword>analgesia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leiomyoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
    <mesh_term>Ropivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 2, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/55/NCT02270255/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Between April 2015 and February 2017, 87 patients were approached for enrollment. All patients fit the inclusion criteria, and no patients were excluded. However, 43 of the 87 patients (49%) declined participation in the study, leaving 44 patients (51%) who agreed to participate.</recruitment_details>
      <pre_assignment_details>No enrolled participants were excluded from the study. Data were complete for all participants up to the time of discharge from the postanesthesia care unit (PACU). Forty-three of the 44 participants (98%) completed the home survey; one participant (2%) was lost to follow-up.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Control Group</title>
          <description>Sham procedure. Subcutaneous injection of 5cc of 1% Xylocaine in the periumbilical region.
Subcutaneous injection: Injection into subcutaneous tissues in periumbilical region
1% Xylocaine: 5ml of 1% Xylocaine</description>
        </group>
        <group group_id="P2">
          <title>Sup Hypogastric Nerve Block Group</title>
          <description>Superior hypogastric nerve block performed during UFE. 20cc of 0.75% Ropivacaine injected at the superior hypogastric nerve plexus.
Superior hypogastric nerve block: 21g Chiba needle advanced into the superior hypogastric plexus via an anterior infraumbilical approach using the arterial catheter as a fluoroscopic landmark to target the vertebral body below.
0.75% Ropivacaine: 20 ml of 0.75% Ropivacaine</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Complete Data at Discharge PACU</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Complete Data From Home Survey</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Same as assignment population.</population>
      <group_list>
        <group group_id="B1">
          <title>Control Group</title>
          <description>Sham procedure. Subcutaneous injection of 5cc of 1% Xylocaine in the periumbilical region.
Subcutaneous injection: Injection into subcutaneous tissues in periumbilical region
1% Xylocaine: 5ml of 1% Xylocaine</description>
        </group>
        <group group_id="B2">
          <title>Sup Hypogastric Nerve Block Group</title>
          <description>Superior hypogastric nerve block performed during UFE. 20cc of 0.75% Ropivacaine injected at the superior hypogastric nerve plexus.
Superior hypogastric nerve block: 21g Chiba needle advanced into the superior hypogastric plexus via an anterior infraumbilical approach using the arterial catheter as a fluoroscopic landmark to target the vertebral body below.
0.75% Ropivacaine: 20 ml of 0.75% Ropivacaine</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="22"/>
            <count group_id="B2" value="22"/>
            <count group_id="B3" value="44"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="22"/>
                    <count group_id="B2" value="22"/>
                    <count group_id="B3" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="22"/>
                    <count group_id="B2" value="22"/>
                    <count group_id="B3" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46" spread="5.2"/>
                    <measurement group_id="B2" value="47" spread="5.7"/>
                    <measurement group_id="B3" value="46.5" spread="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="22"/>
                    <count group_id="B2" value="22"/>
                    <count group_id="B3" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <description>McGill University Health Centre</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="22"/>
                    <count group_id="B2" value="22"/>
                    <count group_id="B3" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Pain sensitivity</title>
          <description>Person self-evaluation of pain of vaccine on scale of 0-10/10 Visual analog scale (VAS). Patient rates pain on a scale from 0 to 10, 0 being no pain at all and 10 being the worse pain they could ever imagine.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="22"/>
                    <count group_id="B2" value="22"/>
                    <count group_id="B3" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.2" spread="2.2"/>
                    <measurement group_id="B2" value="3.5" spread="2.3"/>
                    <measurement group_id="B3" value="3.35" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Pain of regular menstrual cramps</title>
          <description>Patients self-reporting of pain of average menstrual cramp on a scale form 0 to 10 (Visual analog scale - VAS), 0 being no pain at all and 10 being the worse pain they could ever imagine.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="22"/>
                    <count group_id="B2" value="22"/>
                    <count group_id="B3" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.3" spread="2.5"/>
                    <measurement group_id="B2" value="6.9" spread="1.7"/>
                    <measurement group_id="B3" value="6.6" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>mg Equivalent Morphine Used Until Discharge From Recovery Room to Control Pain Level Below 4/10 (VAS)</title>
        <description>mg equivalent morphine used until discharge from recovery room to maintain pain level below 4/10 (visual analog scale 0/10=no pain to 10/10=worse pain the patient could imagine)</description>
        <time_frame>6 hrs (from time of end of UFE to time of discharge from recovery room)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control Group</title>
            <description>Sham procedure. Subcutaneous injection of 5cc of 1% Xylocaine in the periumbilical region.
Subcutaneous injection: Injection into subcutaneous tissues in periumbilical region
1% Xylocaine: 5ml of 1% Xylocaine</description>
          </group>
          <group group_id="O2">
            <title>Sup Hypogastric Nerve Block Group</title>
            <description>Superior hypogastric nerve block performed during UFE. 20cc of 0.75% Ropivacaine injected at the superior hypogastric nerve plexus.
Superior hypogastric nerve block: 21g Chiba needle advanced into the superior hypogastric plexus via an anterior infraumbilical approach using the arterial catheter as a fluoroscopic landmark to target the vertebral body below.
0.75% Ropivacaine: 20 ml of 0.75% Ropivacaine</description>
          </group>
        </group_list>
        <measure>
          <title>mg Equivalent Morphine Used Until Discharge From Recovery Room to Control Pain Level Below 4/10 (VAS)</title>
          <description>mg equivalent morphine used until discharge from recovery room to maintain pain level below 4/10 (visual analog scale 0/10=no pain to 10/10=worse pain the patient could imagine)</description>
          <units>mg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11" spread="9"/>
                    <measurement group_id="O2" value="5.1" spread="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Serious Adverse Reactions From Superior Hypogastric Nerve Block</title>
        <description>Number of patients with Grade C/D/E/F adverse events (Society of Interventional Radiology (SIR) Classification). Per Society of Interventional Radiology (SIR) Classification: Grade C, require therapy, brief hospitalization (&lt;48 hours); Grade D, require major therapy, unplanned increased level of care, prolonged hospitalization (&gt;48 hours); Grade E, permanent adverse sequelae; Grade F, death.</description>
        <time_frame>10 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control Group</title>
            <description>Sham procedure. Subcutaneous injection of 5cc of 1% Xylocaine in the periumbilical region.
Subcutaneous injection: Injection into subcutaneous tissues in periumbilical region
1% Xylocaine: 5ml of 1% Xylocaine</description>
          </group>
          <group group_id="O2">
            <title>Sup Hypogastric Nerve Block Group</title>
            <description>Superior hypogastric nerve block performed during UFE. 20cc of 0.75% Ropivacaine injected at the superior hypogastric nerve plexus.
Superior hypogastric nerve block: 21g Chiba needle advanced into the superior hypogastric plexus via an anterior infraumbilical approach using the arterial catheter as a fluoroscopic landmark to target the vertebral body below.
0.75% Ropivacaine: 20 ml of 0.75% Ropivacaine</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Serious Adverse Reactions From Superior Hypogastric Nerve Block</title>
          <description>Number of patients with Grade C/D/E/F adverse events (Society of Interventional Radiology (SIR) Classification). Per Society of Interventional Radiology (SIR) Classification: Grade C, require therapy, brief hospitalization (&lt;48 hours); Grade D, require major therapy, unplanned increased level of care, prolonged hospitalization (&gt;48 hours); Grade E, permanent adverse sequelae; Grade F, death.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>4-6 months</time_frame>
      <desc>SIR Classification definition of adverse events.</desc>
      <group_list>
        <group group_id="E1">
          <title>Control Group</title>
          <description>Sham procedure. Subcutaneous injection of 5cc of 1% Xylocaine in the periumbilical region.
Subcutaneous injection: Injection into subcutaneous tissues in periumbilical region
1% Xylocaine: 5ml of 1% Xylocaine</description>
        </group>
        <group group_id="E2">
          <title>Sup Hypogastric Nerve Block Group</title>
          <description>Superior hypogastric nerve block performed during UFE. 20cc of 0.75% Ropivacaine injected at the superior hypogastric nerve plexus.
Superior hypogastric nerve block: 21g Chiba needle advanced into the superior hypogastric plexus via an anterior infraumbilical approach using the arterial catheter as a fluoroscopic landmark to target the vertebral body below.
0.75% Ropivacaine: 20 ml of 0.75% Ropivacaine</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia, transient, from Xylocaine with epi injection</sub_title>
                <description>To ensure no intravascular injection of long-acting block agent, a test dose of Xylocaine with epi is injected. One patient had a transient tachycardia confirming intravascular uptake and needing change in needle position.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Pain during the block procedure itself</sub_title>
                <description>Temporary discomfort/pain during placement of the block needle.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Temporary heat sensation in foot</sub_title>
                <description>Presumably from sympathetic chain blockade</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Temporary heaviness in foot</sub_title>
                <description>Resolved by the end of the time in the PACU</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Hard fibroid needing use of 18g needle</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aspiration of blood</sub_title>
                <description>Aspiration of blood prior to injecting anesthetic, needing needle repositioning.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Small number of patients. Single centre study. Occasional use of different narcotics needing morphine equivalent calculations. SHAM procedure did not place a needle as deep as in the study group.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Louis-Martin boucher</name_or_title>
      <organization>McGill University Health Centre</organization>
      <phone>5149341934 ext 44454</phone>
      <email>lmboucher@yahoo.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

